## Amol K Narang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10421287/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Annals of Surgery, 2019, 270, 340-347.	2.1	280
2	The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 259-265.	0.6	171
3	Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With Cancer. JAMA Oncology, 2017, 3, 757.	3.4	171
4	Trends in Advance Care Planning in Patients With Cancer. JAMA Oncology, 2015, 1, 601.	3.4	110
5	Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital - Mayo Clinic collaborative study. Radiation Oncology, 2011, 6, 126.	1.2	95
6	Early Mortality Risk Score: Identification of Poor Outcomes Following Upfront Surgery for Resectable Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2012, 16, 753-761.	0.9	48
7	Socioeconomic factors affect the selection of proton radiation therapy for children. Cancer, 2017, 123, 4048-4056.	2.0	46
8	Evaluation of Adjuvant Radiation Therapy for Resected Gallbladder Carcinoma: A Multi-institutional Experience. Annals of Surgical Oncology, 2015, 22, 1100-1106.	0.7	32
9	Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation. International Journal of Radiation Oncology Biology Physics, 2016, 94, 254-262.	0.4	31
10	Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective. Annals of Surgical Oncology, 2018, 25, 280-289.	0.7	31
11	Adjuvant Chemoradiotherapy is Associated with Improved Survival for Patients with Resected Gallbladder Carcinoma: A Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2018, 25, 255-264.	0.7	29
12	Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation. Practical Radiation Oncology, 2012, 2, 77-85.	1.1	28
13	Stereotactic body radiation therapy for palliative management of pancreatic adenocarcinoma in elderly and medically inoperable patients. Oncotarget, 2018, 9, 16427-16436.	0.8	28
14	Feasibility of Using Hydrogel Spacers for Borderline-Resectable and Locally Advanced Pancreatic Tumors. Gastroenterology, 2019, 157, 933-935.	0.6	20
15	Progressive Low-Grade Glioma: Assessment of Prognostic Importance of Histologic Reassessment and MRI Findings. World Neurosurgery, 2017, 99, 751-757.	0.7	19
16	Longitudinal Trends of Financial Toxicity in Patients With Lung Cancer: A Prospective Cohort Study. JCO Oncology Practice, 2021, 17, e1094-e1109.	1.4	18
17	Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity. Annals of Surgical Oncology. 2022. 29. 2456-2468.	0.7	12
18	Accuracy of Marketing Claims by Providers of Stereotactic Radiation Therapy. Journal of Oncology Practice, 2013, 9, 57-62.	2.5	11

Amol K Narang

#	Article	IF	CITATIONS
19	The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma. Pancreas, 2019, 48, 585-589.	0.5	10
20	Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 309.e7-309.e14.	0.8	8
21	Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy. Radiation Oncology, 2021, 16, 242.	1.2	7
22	Fiducial-based image-guided SBRT for pancreatic adenocarcinoma: Does inter-and intra-fraction treatment variation warrant adaptive therapy?. Radiation Oncology, 2021, 16, 53.	1.2	6
23	High neutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resectable and locally advanced pancreatic cancer. Journal of Gastrointestinal Oncology, 2022, 13, 368-379.	0.6	6
24	Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant chemotherapy and stereotactic body radiotherapy followed by surgical resection. Radiation Oncology Journal, 2021, 39, 304-314.	0.7	6
25	Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy. Radiation Oncology Journal, 2022, 40, 111-119.	0.7	6
26	Prevalence of Substance Use in Patients With Cancer Receiving Radiation Therapy. Clinical Journal of Oncology Nursing, 2016, 20, 397-402.	0.3	5
27	Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy. Advances in Radiation Oncology, 2018, 3, 601-610.	0.6	5
28	Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial. Practical Radiation Oncology, 2022, 12, 511-523.	1.1	5
29	Neoadjuvant Short-Course Radiation Therapy for Rectal Cancer: Trends and Controversies. Current Oncology Reports, 2018, 20, 68.	1.8	4
30	Readmission Adversely Affects Survival in Surgical Rectal Cancer Patients. World Journal of Surgery, 2019, 43, 2506-2517.	0.8	4
31	A rare case of esophageal metastasis from pancreatic ductal adenocarcinoma: a case report and literature review. Oncotarget, 2017, 8, 100942-100950.	0.8	4
32	Structured CT reporting of pancreatic ductal adenocarcinoma: impact on completeness of information and interdisciplinary communication for surgical planning. Abdominal Radiology, 2022, 47, 704-714.	1.0	4
33	The Promise of Modern Radiotherapy in Resected Pancreatic Adenocarcinoma: A Response to Bekaii-Saab et al Annals of Surgical Oncology, 2014, 21, 1064-1066.	0.7	2
34	Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers. Advances in Radiation Oncology, 2018, 3, 42-51.	0.6	2
35	Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 100, 486-489.	0.4	2
36	Upfront Chemotherapy Followed by Stereotactic Body Radiation Therapy with or without Surgery in Older Patients with Localized Pancreatic Cancer: A Single Institution Experience and Review of the Literature. Current Oncology, 2022, 29, 308-320.	0.9	2

Amol K Narang

#	Article	IF	CITATIONS
37	Contemporary Radiation Therapy in Combined Modality Therapy for Hodgkin Lymphoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 597-605.	2.3	1
38	Case volume and improved outcomes across cancer care. Nature Reviews Urology, 2016, 13, 186-187.	1.9	1
39	Stereotactic Ablative Radiotherapy (SABR/SBRT) for Hepatocellular Carcinoma. Current Hepatology Reports, 2018, 17, 392-398.	0.4	1
40	Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediateâ€risk prostate cancer at high risk of distant recurrence and cancerâ€specific mortality. Prostate, 2018, 78, 623-630.	1.2	0